Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 13/20 | 0.41 |
| ▸ | PHGDH | O43175 | 2/20 | 0.34 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27834195 | 0.83 | IRAK4 (0.37) | IRAK4PHGDHFLT3GRIN2BIRAK1 | |
| SCHEMBL720492 | 0.81 | IRAK4 (0.41) | IRAK4PHGDHFLT3DRD2DRD3 | |
| SCHEMBL719035 | 0.80 | ACACB (0.35) | IRAK4PHGDHFLT3DRD2DRD3 | |
| SCHEMBL718319 | 0.75 | ADRB1 (0.37) | — | |
| SCHEMBL718337 | 0.75 | DRD3 (0.36) | DRD2DRD3HTR1ADRD4HTR2A | |
| SCHEMBL27852363 | 0.72 | RAB9A (0.56) | DRD2TSHRMAPK1HSD17B10 | |
| SCHEMBL1806117 | 0.71 | NOTUM (0.46) | TSHRMAPK1HSD17B10 | |
| SCHEMBL719685 | 0.70 | HSD17B10 (0.59) | TSHRMAPK1HSD17B10 | |
| SCHEMBL6035150 | 0.70 | ACACB (0.37) | IRAK4DRD2DRD3GRIN2B | |
| SCHEMBL1805973 | 0.68 | KDM4E (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | IRAK4 3062/4885PHGDH 2726/4885FLT3 2154/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | IRAK4 3062/4885PHGDH 2726/4885FLT3 2154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.